Canandaigua National Bank Trust Co buys $6,110,688 stake in Pfizer (PFE)

Pfizer (PFE) : Canandaigua National Bank Trust Co scooped up 3,300 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 165,826 shares of Pfizer which is valued at $6,110,688.Pfizer makes up approximately 1.74% of Canandaigua National Bank Trust Co’s portfolio.

Other Hedge Funds, Including , Calamos Advisors reduced its stake in PFE by selling 6,979 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 2,848,774 shares of PFE which is valued at $104,977,322. Pfizer makes up approx 0.95% of Calamos Advisors’s portfolio.Excalibur Management Corp reduced its stake in PFE by selling 1,055 shares or 0.56% in the most recent quarter. The Hedge Fund company now holds 186,068 shares of PFE which is valued at $6,856,606. Pfizer makes up approx 5.80% of Excalibur Management Corp’s portfolio.Telemus Capital boosted its stake in PFE in the latest quarter, The investment management firm added 5,930 additional shares and now holds a total of 24,951 shares of Pfizer which is valued at $915,203. Pfizer makes up approx 0.11% of Telemus Capital’s portfolio.Trust Co Of Vermont boosted its stake in PFE in the latest quarter, The investment management firm added 10,421 additional shares and now holds a total of 226,041 shares of Pfizer which is valued at $8,291,184. Pfizer makes up approx 1.07% of Trust Co Of Vermont’s portfolio.Foundation Resource Management Inc reduced its stake in PFE by selling 1,625 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 1,572,651 shares of PFE which is valued at $56,804,154. Pfizer makes up approx 10.51% of Foundation Resource Management Inc’s portfolio.

Pfizer opened for trading at $36.68 and hit $36.95 on the upside on Friday, eventually ending the session at $36.89, with a gain of 0.60% or 0.22 points. The heightened volatility saw the trading volume jump to 2,15,13,828 shares. Company has a market cap of $223,732 M.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Investors should note that on Jun 23, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Sep 1, 2016.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *